Answers are grounded in this paper and cite their sources.
Reviews clinical trials evaluating stem cell therapy for ischemic myocardial injury, highlighting consistent safety alongside heterogeneous efficacy outcomes.
Following encouraging preclinical animal data, stem cell therapy has been tested in a variety of clinical trials in patients with both acute and chronic ischemic myocardial injury with the goal of repairing damaged myocardium and/or inducing the growth of new blood vessels so as to improve cardiac function and symptoms. Many cell types have been studied, but most clinical trials to date have utilized autologous bone marrow mononuclear cells (or cellular fractions thereof) with good safety data but heterogeneous results in terms of efficacy.
No takes yet. Share an insight, caveat, or question.
Oldroyd et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: